NO953684L - Method of Preparing Cancer Vaccines - Google Patents

Method of Preparing Cancer Vaccines

Info

Publication number
NO953684L
NO953684L NO953684A NO953684A NO953684L NO 953684 L NO953684 L NO 953684L NO 953684 A NO953684 A NO 953684A NO 953684 A NO953684 A NO 953684A NO 953684 L NO953684 L NO 953684L
Authority
NO
Norway
Prior art keywords
dna
cancer vaccines
preparing cancer
binding substance
complex
Prior art date
Application number
NO953684A
Other languages
Norwegian (no)
Other versions
NO953684D0 (en
Inventor
Max L Birnstiel
Michael Buschle
Matthew Cotten
Gerhard Maass
Christian Plank
Gotthold Schaffner
Walter Schmidt
Ernst Wagner
Kurt Zatloukal
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0055693A external-priority patent/AT399656B/en
Priority claimed from DE4326821A external-priority patent/DE4326821A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO953684L publication Critical patent/NO953684L/en
Publication of NO953684D0 publication Critical patent/NO953684D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Kreftvaksine oppnås ved behandling av tumorceller eller fibroblaster med et kompleks av DNA som koder for et immun- stimulerende polypeptid, og en DNA-bindende substans, f.eks. polylysin, som fortrinnsvis er konjugert med transferrin. Komplekset inneholder videre et konjugat av DNA-bindende substans og et til dette ionisk bundet endosomolytisk peptid eller et adenovirus, som oppviser i det minste en E4-defekt.Cancer vaccine is obtained by treating tumor cells or fibroblasts with a complex of DNA encoding an immunostimulating polypeptide, and a DNA-binding substance, e.g. polylysine, which is preferably conjugated with transferrin. The complex further contains a conjugate of DNA-binding substance and an endosomolytic peptide or adenovirus bound thereto, which exhibits at least one E4 defect.

NO953684A 1993-03-19 1995-09-18 Method of Preparing Cancer Vaccines NO953684D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0055693A AT399656B (en) 1993-03-19 1993-03-19 Process for the production of cancer vaccines
DE4326821A DE4326821A1 (en) 1993-08-10 1993-08-10 New cancer vaccine based on autologous, transfected tumour cells
PCT/EP1994/000859 WO1994021808A1 (en) 1993-03-19 1994-03-18 Process for preparing cancer vaccines

Publications (2)

Publication Number Publication Date
NO953684L true NO953684L (en) 1995-09-18
NO953684D0 NO953684D0 (en) 1995-09-18

Family

ID=25593140

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953684A NO953684D0 (en) 1993-03-19 1995-09-18 Method of Preparing Cancer Vaccines

Country Status (13)

Country Link
EP (1) EP0689604A1 (en)
JP (1) JPH08507921A (en)
KR (1) KR960701211A (en)
CN (1) CN1119459A (en)
AU (1) AU6427994A (en)
CA (1) CA2158655A1 (en)
CZ (1) CZ241795A3 (en)
FI (1) FI954383L (en)
HU (1) HUT73383A (en)
NO (1) NO953684D0 (en)
NZ (1) NZ263550A (en)
PL (1) PL311036A1 (en)
WO (1) WO1994021808A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
WO1995031105A1 (en) * 1994-05-13 1995-11-23 Thomas Jefferson University A method of inducing an immune response using vaccinia virus recombinants
DE4426429A1 (en) * 1994-07-26 1996-02-01 Boehringer Ingelheim Int Method for introducing DNA into higher eukaryotic cells
DE19510344C1 (en) * 1995-03-22 1996-11-07 Boehringer Ingelheim Int Use of a tumor vaccine
WO1997000085A1 (en) * 1995-06-19 1997-01-03 University Of Medicine & Dentistry Of New Jersey Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
DE19608751B4 (en) 1996-03-06 2006-05-18 Medigene Ag Use of an adeno-associated virus vector to increase the immunogenicity of cells
DE19608753C1 (en) * 1996-03-06 1997-06-26 Medigene Gmbh Transduction system based on rep-negative adeno-associated virus vector
DE19631357A1 (en) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vector for activating the immune system against cells associated with papilloma viruses or sequences thereof
CN100352511C (en) * 1997-08-13 2007-12-05 Uab研究基金会 Vaccination by topical application of genetic vectors
CA2299429C (en) 1997-08-13 2010-04-20 Biontex Laboratories Gmbh New lipopolyamines,their preparation and the use thereof
WO1999036433A2 (en) 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
US7795020B2 (en) 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines
WO1999042121A1 (en) * 1998-02-20 1999-08-26 University Of Miami Modified heat shock protein-antigenic peptide complex
CA2362578A1 (en) 1999-02-09 2000-08-17 Kam Leong Tumor vaccines
BR0001029A (en) * 2000-04-10 2001-11-20 Fk Biotecnologia Ltda Process of transformation of tumor cells
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10131148A1 (en) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogenic oligo- and / or polyribonucleotides as agents for the treatment of malignant tumors
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
DK2257301T3 (en) 2008-03-03 2014-04-28 Univ Miami Immunotherapy based on allogeneic cancer cells.
JP2011515399A (en) 2008-03-20 2011-05-19 ユニバーシティー オブ マイアミ Heat shock protein GP96 vaccination and method using the same
MY166516A (en) * 2010-12-02 2018-07-05 Oncotherapy Science Inc Tomm34 peptides and vaccines including the same
SG11201705844SA (en) 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
CA3031806A1 (en) * 2016-07-25 2018-02-01 Ascend Biopharmaceuticals Ltd Methods of treating cancer
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
AU2018395010B2 (en) * 2017-12-29 2022-07-28 Genemedicine Co., Ltd. Cell sheet for gene delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation

Also Published As

Publication number Publication date
WO1994021808A1 (en) 1994-09-29
FI954383A7 (en) 1995-09-18
FI954383A0 (en) 1995-09-18
JPH08507921A (en) 1996-08-27
CN1119459A (en) 1996-03-27
PL311036A1 (en) 1996-01-22
CZ241795A3 (en) 1996-04-17
CA2158655A1 (en) 1994-09-29
HUT73383A (en) 1996-07-29
NZ263550A (en) 1996-12-20
HU9502720D0 (en) 1995-11-28
AU6427994A (en) 1994-10-11
KR960701211A (en) 1996-02-24
EP0689604A1 (en) 1996-01-03
NO953684D0 (en) 1995-09-18
FI954383L (en) 1995-09-18

Similar Documents

Publication Publication Date Title
NO953684L (en) Method of Preparing Cancer Vaccines
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
DK0835133T3 (en) Recombinant smallpox virus rabies and combination preparations and their uses
ATE332386T1 (en) DEFECTIVE RECOMBINANT ADENOVIRUSES FOR TUMOR GENE THERAPY
PH25747A (en) Recombinant vaccinia vrus mva
DE69333815D1 (en) Gene Transformation and Ionizing Radiation: Methods and Compositions
BR9908823A (en) Lung cancer therapy and diagnosis compounds and processes
DE69731611D1 (en) A composition containing a detergent and an adenoviral vector encoding a tumor suppressor gene
CA2283462A1 (en) Vectors having enhanced expression and methods of making and uses thereof
IL122408A0 (en) Dna encoding a trail polypeptide and its preparation
TW428026B (en) Bifunctional protein, preparation and use
WO1995031559A3 (en) Methods of inducing gene expression by ionizing radiation
NO952039L (en) Proteins with glycosyltransferase activity
DE68915165D1 (en) IMMUNOGENIC SECTIONS OF HUMAN PARAIN INFLUENCE VIRUS TYPE 3 CONTAINING CHIMERIC GLYCOPROTEINS.
ATE424410T1 (en) INTERLEUKIN-19.
DK0889969T3 (en) Recombinant adenoviral for gene therapy of human tumors
DK1253201T3 (en) Chicken anemia virus mutants and vaccines based on the viral protein VP3 or sequences of this virus encoding therefore
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
WO1994016085A3 (en) Hybrid proteins having cross-linking and tissue-binding activities
BR0016740A (en) Cryptosporidium sporozoite antigens